A diagnostic test, which uses the ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) to predict the short-term risk of developing preeclampsia [26], may help optimize patient management by triaging those at low risk of preeclampsia to an outpatient setting, while ensuring higher-risk patients are managed more intensively. Here, FLT1 is linked to preeclampsia.